NT
Intellia Therapeutics, Inc.
NTLA · NASDAQ
$12.21 -2.32% (-$0.29)
1M +1.58%
Market Cap $1.71B
P/E Ratio -
Div. Yield -
ROE 57.79%
Piotroski F-Score Weak
3/9Valuation
40 /100
Fair P/B 2.34x
P/S 28.67x
PEG N/A
Growth
49 /100
Stable Book val. growth 18.40%
Rev. growth 9.09%
FCF growth N/A
Profitability
0 /100
Weak FCF margin 783.30%
Op. margin 711.66%
Gross margin 46.48%
Quality
1 /100
Poor Asset turnover 0.07x
ROA 46.66%
ROIC 52.86%
Debt
100 /100
Low Current ratio 6.65x
Debt/Equity 0.10x
Net debt/EBITDA N/A
Stability
33 /100
Unstable Profitable years 0
EPS volatility 12.29%
Beta 1.82x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na NTLA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Leonard
Employees
377
Headquarters
Cambridge
Nadcházející události
05 LIS
Earnings
Upcoming earnings report